top of page

KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases. 

Our Company
City Skyline Across The Water

KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China. 

Image by Tim Bogdanov

We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.

Image by Michael Longmire

We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials. 

About KLUS
Our Approach

Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.

bispecific antibodies 3.jpg

Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA. 


Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR. 

Aug 10, 2023

Selected for mini-oral presentation at 2023 ESMO: Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC)

Jul 11, 2023

Kelun-Biotech officially debuts with HK$13.58 billion IPO on HKEX

Jun 19, 2023

CTA of Kelun-Biotech's TROP2-ADC (SKB264, MK-2870) in combination with pembrolizumab is approved in the European Union.

Recent News
bottom of page